Advertisement
U.S. markets open in 9 hours 11 minutes

Clearside Biomedical, Inc. (CLSD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.2900+0.0400 (+3.20%)
At close: 04:00PM EST
1.4200 +0.13 (+10.08%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close1.2500
Open1.2500
Bid1.2700 x 800
Ask1.3000 x 1400
Day's Range1.2000 - 1.3000
52 Week Range0.6500 - 1.5400
Volume123,196
Avg. Volume186,267
Market Cap96.39M
Beta (5Y Monthly)2.31
PE Ratio (TTM)N/A
EPS (TTM)-0.6100
Earnings DateMar 07, 2024 - Mar 11, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CLSD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Clearside Biomedical, Inc.
    Daily – Vickers Top Buyers & Sellers for 02/12/2024The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    9 days agoArgus Research
View more
  • Simply Wall St.

    Pleasing Signs As A Number Of Insiders Buy Clearside Biomedical Stock

    When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

  • GlobeNewswire

    Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering

    ALPHARETTA, Ga., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (“Clearside” or the “Company”) (NASDAQ: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it has entered into a securities purchase agreement with institutional investors and an existing stockholder, providing for the purchase and sale of 11,111,111 shares of common stock and accompanying warrant to purchase

  • GlobeNewswire

    Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

    - CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside’s SCS Microinjector® - - Randomization Completed in ODYSSEY Phase 2b Clinical Trial - - Topline Data Expected in Q3 2024 - ALPHARETTA, Ga., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it has completed randomization